Drugs / PN-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04976140 | Dec 2021 → Oct 2023 | dermatomyositis | Paean Biotechnology Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07122648 | Dec 2025 → Apr 2027 expected | dermatomyositis | Paean Biotechnology Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PN-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04976140 ↗ |
| Route | Intravenous | “the investigator intravenously administers a single-dose of the investigational product according to the planned dose.” NCT04976140 ↗ |